31 completed, 5 terminated, 2 withdrawn. 21 Phase 1, 19 Phase 2, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 16, Terminated 4, Withdrawn 1 |
| Phase 2 | 19 | Completed 18, Withdrawn 1 |
| Not applicable | 3 | Completed 2, Terminated 1 |
Follow Recurrent Squamous Cell Carcinoma of the Nasopharynx: new trials by email Literature Review of Recurrent Squamous Cell Carcinoma of the Nasopharynx trials Research Report on Recurrent Squamous Cell Carcinoma of the Nasopharynx
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck sorafenib tosylate, cisplatin, docetaxel - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 3 | 2014-04-14 | 2018-05-24 |
| Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy acetylcysteine, placebo, quality-of-life assessment - Mucositis, Oral Complications | Phase 2 | Completed | Mayo Clinic | 34 | 2014-04-01 | 2019-04-30 |
| Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy entolimod, intensity-modulated radiation therapy, cisplatin - Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2014-01-01 | 2013-12-11 | |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection vorinostat, diagnostic laboratory biomarker analysis, pharmacological study - HIV Infection, Recurrent Anal Cancer | Phase 1 | Terminated | AIDS Malignancy Consortium | 17 | 2013-11-01 | 2020-07-29 |
| Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy placebo, quality-of-life assessment, questionnaire administration - Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-05-01 | 2013-05-15 | |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Completed | University of Chicago | 48 | 2013-03-26 | 2024-07-31 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer talactoferrin, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | Stanford University | 4 | 2012-05-01 | 2016-08-02 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | University of Washington | 13 | 2011-06-01 | 2015-03-05 |
| Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer transoral robotic surgery, laboratory biomarker analysis, quality-of-life assessment - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Lymphoepithelioma of the Nasopharynx | Not applicable | Terminated | City of Hope Medical Center | 7 | 2011-04-01 | 2014-11-10 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Akt inhibitor MK2206 - Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2011-04-01 | 2017-12-05 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer cetuximab, paclitaxel, carboplatin - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | Fox Chase Cancer Center | 24 | 2011-02-16 | 2018-02-26 |
| L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer quality-of-life assessment, management of therapy complications, L-lysine - Mucositis, Oral Complications of Chemotherapy | Not applicable | Completed | University of Washington | 10 | 2010-09-01 | 2013-05-17 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab cetuximab, placebo, sorafenib tosylate - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2026-03-10 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer everolimus, cetuximab, pharmacological study - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Fox Chase Cancer Center | 12 | 2008-11-01 | 2012-07-11 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2008-07-01 | 2013-07-02 |
| Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer pazopanib hydrochloride, pharmacological study, computed tomography - Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Nasopharynx | Phase 2 | Completed | National Cancer Institute (NCI) | 33 | 2007-08-01 | 2015-12-17 |
| Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer saracatinib, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2007-07-01 | 2014-04-30 |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer dasatinib, pharmacological study, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2007-07-01 | 2014-10-01 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer bevacizumab, placebo, magnetic resonance imaging - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2007-06-01 | 2014-05-09 |
Showing 20 of 38. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (36) · Salivary Gland Neoplasms (27) · Tongue Neoplasms (19) · Esthesioneuroblastoma, Olfactory (10) · Carcinoma, Non-Small-Cell Lung (9) · Colonic Neoplasms (7) · Carcinoma, Ovarian Epithelial (6) · Anus Neoplasms (5) · Breast Neoplasms (5) · Esophageal Neoplasms (5) · Pancreatic Neoplasms (5) · Rectal Neoplasms (5) · Stomach Neoplasms (5) · Carcinoma, Hepatocellular (4) · Mucositis (4)
Carcinoma (36) · Head and Neck Neoplasms (36) · Neoplasms by Histologic Type (36) · Neoplasms by Site (36) · Neoplasms, Glandular and Epithelial (36) · Carcinoma, Squamous Cell (35) · Neoplasms (35) · Mouth Diseases (31) · Mouth Neoplasms (31) · Stomatognathic Diseases (31) · Salivary Gland Diseases (27) · Tongue Diseases (19) · Digestive System Diseases (12) · Gastrointestinal Diseases (12) · Neoplasms, Germ Cell and Embryonal (11)
Cetuximab (8) · Erlotinib Hydrochloride (7) · Bevacizumab (4) · Carboplatin (3) · Sorafenib (3) · Taxes (3) · Cisplatin (2) · Docetaxel (2) · Fluorouracil (2) · Hydroxyurea (2) · Irinotecan (2) · Lapatinib (2) · Paclitaxel (2) · Pharmacogenomic Testing (2) · Radiation (2)
National Cancer Institute (NCI) (24) · Roswell Park Cancer Institute (3) · Fox Chase Cancer Center (2) · University of Chicago (2) · University of Washington (2) · AIDS Malignancy Consortium (1) · City of Hope Medical Center (1) · Mayo Clinic (1) · Ohio State University Comprehensive Cancer Center (1) · Stanford University (1)
United States (35) · Singapore (2) · China (1)
Anurag Singh (2) · Ezra Cohen (2) · Jill Gilbert (2) · Tanguy Seiwert (2) · Alain Mita (1) · Antonius Miller (1) · Barbara Burtness (1) · Brigette Ma (1) · Charles Rudin (1) · Christopher Thomas (1) · David Gustin (1) · David Solit (1) · Ellie Maghami (1) · Eric Kraut (1) · Everett Vokes (1)
PMID 19201650, PMID 23868427, PMID 25057165, PMID 26928328, PMID 31405750, PMID 35429391, PMID 35945244, PMID 40166973
N01CM62201 (4), N01CM62202 (2), P30CA014599 (2), P30CA015083 (2), P30CA016672 (2), U01CA076576 (2), U10CA032102 (2), N01CM00099 (1), N01CM00100 (1), N01CM17102 (1), N01CM62206 (1), N01CM62209 (1), P30CA006927 (1), P30CA015704 (1), P30CA044579 (1)